The start of any new act in Valorant is a pretty big one, and that is also true for Act 3, which comes as a part of the 12.08 ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data from two ...

The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) ...

(UroToday.com) The 2026 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Johann S. De Bono discussing preliminary phase 1 dose escalation results of VIR-5500 ...

Here’s what to know about the 12-3-30 workout. By Danielle Friedman See more of our coverage in your search results.Encuentra más de nuestra cobertura en los resultados de búsqueda. Add The New York ...

The biggest stories of the day delivered to your inbox.

Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.

Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK inhibitor to a 12% reduction in the risk of disability progression compared to ...

Contract strengthens the company’s growing portfolio of U.S. government-funded PNT initiatives TrustPoint has been awarded a $1.9 million Small Business Innovation Research (SBIR) Direct-to-Phase II ...

As the days counted down leading up to Thursday’s trade deadline, the main question on the minds of Los Angeles Lakers’ fans was what move, or moves, would the team make. That question was answered in ...

China's YMTC is fast-tracking construction of its Wuhan Phase III NAND flash fab, bringing its mass production target forward to the second half of 2026, roughly a year ahead of the original 2027 ...